Affimed (NASDAQ:AFMD) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Affimed Trading Down 12.7 %

Shares of AFMD opened at $0.96 on Friday. Affimed has a twelve month low of $0.52 and a twelve month high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The company’s fifty day simple moving average is $0.83 and its 200-day simple moving average is $1.61.

Institutional Trading of Affimed

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Affimed in the third quarter worth about $44,000. Intellectus Partners LLC lifted its stake in shares of Affimed by 34.0% during the 4th quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in Affimed during the fourth quarter valued at about $218,000. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.